Advertisement
Journal Home
Search for

Volume 26, Issue 3, Pages 255-262 (March 2010)


View previous. 5 of 24 View next.

Breast cancer survivors and vitamin D: A review

Stephanie L. Hines, M.D.aCorresponding Author Informationemail address, H. Keels S. Jorn, M.D.b, Kristine M. Thompson, M.D.c, Jan M. Larson, M.D.d

Received 21 May 2009; accepted 17 August 2009. published online 09 December 2009.

Abstract 

Recent evidence has suggested a role for vitamin D in breast cancer prevention and survival. Studies have reported an inverse relation between vitamin D intake and the risk of breast cancer, improvements in survival after a diagnosis of breast cancer in women with higher levels of vitamin D, and vitamin D insufficiency in up to 75% of women with breast cancer. Preclinical data have indicated that vitamin D affects up to 200 genes that influence cellular proliferation, apoptosis, angiogenesis, terminal differentiation of normal and cancer cells, and macrophage function. Vitamin D receptors have been found in up to 80% of breast cancers, and vitamin D receptor polymorphisms have been associated with differences in survival. Although ongoing studies have investigated a possible link between adequate levels of vitamin D and improved cancer prognosis, breast cancer survivors may derive additional, non–cancer-related benefits from adequate vitamin D levels, including improvements in bone mineral density, quality of life, and mood. Maintaining adequate vitamin D stores is recommended for breast cancer survivors throughout their lifetime.

a Division of Consultative and Diagnostic Medicine, Mayo Clinic, Jacksonville, Florida, USA

b Division of Community Internal Medicine, Mayo Clinic, Jacksonville, Florida, USA

c Department of Emergency Medicine, Mayo Clinic, Jacksonville, Florida, USA

d Department of Family Medicine, Mayo Clinic, Jacksonville, Florida, USA

Corresponding Author InformationCorresponding author. Tel.: +1-507-284-8917; fax: +1-507-284-2107.

 Dr. Hines received research grants from Novartis, Sanofi-Aventis, and AstraZeneca for research in bone studies in patients with breast cancer using bisphosphonates (no relation to the present study).

PII: S0899-9007(09)00362-1

doi:10.1016/j.nut.2009.08.020


View previous. 5 of 24 View next.

Advertisement